Myasthenia gravis (MG) is an autoimmune disease involving the thymus in which 85% of patients have antibodies to muscle acetylcholine receptors (AchR-Ab) that interfere with neuromuscular transmission and can cause severe, sometimes life-threatening, weakness. Thymectomy has been used world-wide to treat non-thymomatous MG, based on retrospective non-randomized studies. Prednisone (a corticosteroid) is also frequently used to treat MG. Both therapies are often employed together and both have adverse effects. Whether thymectomy benefits those who are also receiving prednisone is not known. To investigate the safety while comparing efficacy, we propose a multicenter, multiracial, international, single-blinded, 3-year duration clinical trial in which patients aged 18-60 years with generalized AchR-Ab positive non- thymomatous MG are randomized to receive extended transsternal thymectomy (ETTX) or no thymectomy. Both groups will receive prednisone administered by a 'blind' evaluator according to the same set protocol aimed at establishing the minimum dose needed to achieve and maintain Minimal Manifestation (MM) status. The primary endpoint will comprise response and toxicity using a composite measuring clinical course, short and long term toxicities based on: (a) clinical efficacy of therapy evaluated by the QMG weakness score (b) frequency of serious adverse events (c) the total dose of prednisone (Area under the Dose time Curve, AUDTC). A significant difference favoring ETTX would establish its clinical benefits in this patient population, and provide indirect evidence of the possible benefits of ETTX in patients not receiving prednisone medication. Conversely, failure to demonstrate a significant difference in the global or individual components of the primary endpoint would suggest that thymectomy is an unnecessary procedure in the population studied. Subgroup analysis may show whether benefits are confined to those who are prednisone naive at entry or in a particular age group. Thus the results will impact on current clinical practice. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01NS042685-03
Application #
7290468
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Program Officer
Odenkirchen, Joanne
Project Start
2005-09-23
Project End
2010-08-31
Budget Start
2007-09-01
Budget End
2008-08-31
Support Year
3
Fiscal Year
2007
Total Cost
$1
Indirect Cost
Name
University of Alabama Birmingham
Department
Biostatistics & Other Math Sci
Type
Schools of Public Health
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Sengupta, Manjistha; Wang, Bi-Dar; Lee, Norman H et al. (2018) MicroRNA and mRNA expression associated with ectopic germinal centers in thymus of myasthenia gravis. PLoS One 13:e0205464
Weis, Cleo-Aron; Aban, Inmaculada B; Cutter, Garry et al. (2018) Histopathology of thymectomy specimens from the MGTX-trial: Entropy analysis as strategy to quantify spatial heterogeneity of lymphoid follicle and fat distribution. PLoS One 13:e0197435
Wolfe, Gil I; Kaminski, Henry J; Aban, Inmaculada B et al. (2016) Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med 375:511-22
Aban, Inmaculada B; George, Brandon (2015) Statistical considerations for preclinical studies. Exp Neurol 270:82-7
Kaminski, Henry J; Kusner, Linda L; Wolfe, Gil I et al. (2012) Biomarker development for myasthenia gravis. Ann N Y Acad Sci 1275:101-6
Minisman, Greg; Bhanushali, Minal; Conwit, Robin et al. (2012) Implementing clinical trials on an international platform: challenges and perspectives. J Neurol Sci 313:1-6
Kister, Ilya; Chamot, Eric; Bacon, Joshua H et al. (2011) Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium. Mult Scler 17:725-33
Marrie, Ruth Ann; Cutter, Gary; Tyry, Tuula (2011) Substantial adverse association of visual and vascular comorbidities on visual disability in multiple sclerosis. Mult Scler 17:1464-71
Mandawat, Aditya; Kaminski, Henry J; Cutter, Gary et al. (2010) Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol 68:797-805
Marrie, R A; Rudick, R; Horwitz, R et al. (2010) Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 74:1041-7

Showing the most recent 10 out of 15 publications